ClinicalTrials.gg
TerminatedNCT00635076Updated Jan 28, 2021

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

A Phase 4 interventional study of placebo and alprazolam XR in Panic Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 3 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Please see Detailed Description for the termination reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Panic Disorder with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Panic Disorder · United States.

Enrollment
92nd of 94
3 · median 69
Started
2004
with 8 others
Phase 4
18 of 109
none open now
Registered
40th of 109
by date

Among the 109 studies in Panic Disorder with a site in United States, this one is the 92nd largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2004, is one of 18 in phase 4, and was the 40th registered.

Panic Disorder

270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.

Browse Panic Disorder studies →

Open to participants now

9 of the 109 studies in Panic Disorder with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Panic Disorder studies recruiting now, 8 (33%) set no upper age limit and 15 (63%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Panic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.

Read the detailed description

Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.

03

Conditions studied

  • Panic Disorder

Browse trials for

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A primary , Fourth Edition, Text Revision diagnosis of panic disorder with or without agoraphobia based on the Mini-International Neuropsychiatric Interview for Children and Adolescents
  • Subjects with an average of 1) at least one 4-symptom panic attack per week over the last 4 weeks before screening; 2) at least one 4-symptom panic attack per week over the last 4 weeks before baseline; and 3) at least one 4-symptom panic attack in the 7 days prior to baseline
  • To enter Study A6131007, subjects must have completed Study A6131002, had an acceptable tolerability to study drug, and in the clinical judgment of the investigator, could have benefited from continued study treatment.

Exclusion criteria

Exclusion Criteria:

  • Subjects must continue to meet all of the exclusion criteria enumerated in the Acute Efficacy Study (Protocol A6131002) with the following exception: Subjects will be allowed to undergo cognitive-behavioral or other panic-specific therapy and any other psychotherapy (e.g., supportive and/or family therapy) during the expected study period in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Other: placebo

  • Active comparator
    Alprazolam XR group

    Drug: alprazolam XR

Interventions

  • Otherplacebo

    Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).

  • Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.

    Also known as: Xanax XR

06

What researchers measure

Primary outcomes

  1. Baseline-to-peak Physician Withdrawal Checklist change score during taper off Alprazolam

    Time frame: Week 24 (taper baseline), Weeks 25-29, and end of taper visit

  2. The incidence of treatment-emergent adverse events during 6 months of treatment with alprazolam XR

    Time frame: Weeks 6, 8, 12, 16, 20, and 24

  3. Endpoint change from baseline in Digit Symbol-Coding Test, immediate recall, and delayed recall

    Time frame: Week 24

Secondary outcomes

  1. Endpoint change from baseline in Hamilton Anxiety Rating scale

    Time frame: Weeks 12 and 24

  2. Endpoint change compared with baseline in the Panic Disorder Severity Scale - Adolescent Version total and item scores

    Time frame: Weeks 12 an 24

  3. Endpoint compared with baseline for Clinical Global Impression (CGI)-Improvement scale

    Time frame: Weeks 12 and 24

  4. Endpoint change compared with baseline in CGI-Severity score

    Time frame: Weeks 12 and 24

  5. Endpoint compared with baseline in Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score

    Time frame: Weeks 12 and 24

  6. Descriptive estimates of the persistence of safety events and adverse events

    Time frame: Week 24

07

Study locations

3 sites
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Middleton, Wisconsin 53562, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 13, 2008
Start
Jul 2004
CompletionActual
Sep 2004
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635076
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
Jul 2004
Completion
Sep 2004
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alprazolam

Start the discussion